Today there are thousands of diseases that have no treatment and
millions are suffering with no hope for a cure. Patients deserve better.
This is not a world that will emerge, it is a world we must create. The exponential growth and availability of biomedical data present new opportunities to fuse science and technology and re-engineer drug discovery and development. This is what we do.
Every day there are thousands of scientific papers published, hundreds of millions of medical records created, vast amounts of data collected and research completed. Our AI and machine learning models empower scientists to make sense of all of that information to decipher the complex code underlying human biology.DRUG PROGRAMMES
Responding to the global health crisis, we turned our AI platform toward identifying existing drugs that could be used to treat the novel coronavirus. Our research led to a clinical trial with Eli Lilly and the US National Institute for Allergies and Infectious Diseases.
Human intelligence and technology united to re-engineer drug discovery and deliver life-changing medicines.
Our expanding biomedical knowledge base of contextualised machine-curated relationships and proprietary insights represents what is known and can be inferred about a disease.
Data-driven Target ID built on our machine learning models selects and validates the highest quality, hypotheses for novel drug targets.
Applied machine learning models enable scientists to determine the right mechanism to modulate, and identify patient endotypes more likely to respond to treatment.
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment.
"The fragile nature of life and health has never been more apparent, but the partnership of human and artificial intelligence promises to accelerate new discoveries, new therapies and new hope for patients."